Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Department of Endocrinology, Internal Medicine, Soonchunhyang University Hospital, 59, Daesagwan-ro, Yongsan-gu, Seoul, 04401, Republic of Korea.
Calcif Tissue Int. 2019 Mar;104(3):313-319. doi: 10.1007/s00223-018-0493-2. Epub 2018 Nov 16.
Although Asian with bisphosphonate has been considered to have higher risk of subtrochanteric and diaphyseal femur (ST/DF) fractures, the occurrence of those fractures has been still unclear in Asia. The purpose of this study was to investigate the incidence rate of ST/DF fractures among bisphosphonate users from nationwide database in South Korea. Using national health insurance claim database, we only included the bisphosphonate users who took bisphosphonate for the first time in 2008 and evaluated the incidence rate of ST/DF fracture from 2008 to 2013. Non-user controls were matched to bisphosphonate users by propensity score matching with age and gender. Cox regression models were used to calculate hazard ratios of ST/DF fracture with and without adjustment for comorbidity. A total of 682 ST/DF fractures were observed among 348,311 bisphosphonate users. The incidence rate of ST/DF fracture among bisphosphonate users (37.75/100,000 person years, 95% CI 35.02-40.70) was higher compared with non-users (24.41/100,000 person years, 95% CI 22.31-26.71). The risk of ST/DF fracture was greater in bisphosphonate users compared with non-users (hazard ratio 1.541, 1.370-1.734; p < 0.001). The incidence rate of ST/DF fracture after bisphosphonate use could be determined in Korean patients, which can provide basal information for further studies on risk and benefit of continuing bisphosphonate.
尽管亚洲人使用双膦酸盐被认为具有更高的转子下和骨干股骨(ST/DF)骨折风险,但在亚洲,这些骨折的发生情况仍不清楚。本研究的目的是调查韩国全国数据库中双膦酸盐使用者的 ST/DF 骨折发生率。我们仅使用国家健康保险索赔数据库,纳入 2008 年首次使用双膦酸盐的双膦酸盐使用者,并评估 2008 年至 2013 年 ST/DF 骨折的发生率。非使用者对照通过年龄和性别倾向评分匹配与双膦酸盐使用者匹配。Cox 回归模型用于计算未调整和调整合并症的 ST/DF 骨折的风险比。在 348311 名双膦酸盐使用者中观察到 682 例 ST/DF 骨折。双膦酸盐使用者的 ST/DF 骨折发生率(37.75/100000 人年,95%CI 35.02-40.70)高于非使用者(24.41/100000 人年,95%CI 22.31-26.71)。与非使用者相比,双膦酸盐使用者发生 ST/DF 骨折的风险更高(风险比 1.541,1.370-1.734;p<0.001)。在韩国患者中可以确定使用双膦酸盐后 ST/DF 骨折的发生率,这可以为进一步研究继续使用双膦酸盐的风险和获益提供基础信息。